Abstract:
Introduction: Donepezil is a prescription drug to treat mild, moderate, and severe stages of Alzheimer’s disease. By its selective and reversible inhibition on acetylcholinesterase especially in the brain, the
peripheral effects are minimal. These aspects together with its lack of hepatotoxicity represent the advantages of using donepezil towards other drugs, becoming the first line therapy for this pathology. The
secundary effects involve muscarinic cholinergic symptoms (nausea, vomit, diarrhea), as well as nicotinic
N, (insomnia) and N (muscular cramps).
Aim: The paper aims to find and validate a sensitive method for the assay of donepezil in plasma using a non-aqueous capillary electrophoresis method.
Matherials and methods: Donepezil hydrochloride (PhEur.), methanol (HPLC isocratic grade), acetonitrile (HPLC grade), hexane and ammonium acetate of analytical purity were bought from Sigma,
human plasma was obtained from the Haematological Institute in Bucharest. Agilent AG1610 capillary
electrophoresis with diode array detector was used as main analytical instrument. Human plasma samples spiked with known amounts of donepezil were used for the bioanalytical validation of the method,
which was performed according to the EMA guidelines. The method was also tested on real samples tor
patients treated with donepezil.
Results: The non-aqueous capillary electrophoresis method for the donepezil assay in plasma was
performed using as a running buffer a mixture of methanol: acetonitrile (70:30) with 15 mM ammonium
acetate, a silica PVA coated capillary (64 cm length, 50pm i.d.), 10 minutes 50 mbarr hydrodynamic
injection, 30kV applied voltage; detection was performed at 315 nm (which lacks spectral interference
of proteins), but the 268 and 220 nm wavelengths were also monitored. The sample were extracted with
hexane from alkalinized 1:10 diluted plasma, dried under nitrogen flow, and then re-dissolved in a small
amount of mobile phase. Limit of detection obtained was 0.5 pg/mL.
Conclusions: The method is sensitive and can be applied to monitor donepezil hydrochloride plasma
levels in patients treated for Alzheimer’s disease.
